VERTEX PHARMACEUTICALS INC / MA Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount of $24.30 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2025-03-31 was $24.30M.
- VERTEX PHARMACEUTICALS INC / MA equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2024-09-30 was $13.30M.
- VERTEX PHARMACEUTICALS INC / MA equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2024 was $48.20M.
| Period end | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 12 month |
|---|---|---|---|---|
| 2025-03-31 | $24.30M 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $48.20M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $13.30M 10-Q · filed 2025-11-04 | $37.60M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $24.30M 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |